Literature DB >> 10388103

Prognostic Factors in Aggressive Non-Hodgkin's Lymphomas.

.   

Abstract

Aggressive non-Hodgkin's lymphoma (NHL) is a biologically heterogeneous disease that can be cured with aggressive chemotherapy treatment. Different clinical, biological, cellular and molecular features have been identified as having prognostic significance on the outcome of NHL patients. The knowledge of these prognostic features can be used in everyday practice in order to predict the prognosis of every new NHL patient and tailor his or her treatment accordingly.

Entities:  

Year:  1998        PMID： 10388103

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  7 in total

1.  Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).

Authors:  Michael Tallarico; Jared C Foster; Drew Seisler; Jacqueline M Lafky; Arti Hurria; Aminah Jatoi; Harvey J Cohen; Hyman B Muss; Nancy Bartlett; Bruce D Cheson; Sin-Ho Jung; John P Leonard; John C Byrd; Chadi Nabhan
Journal:  J Geriatr Oncol       Date:  2018-04-17       Impact factor: 3.599

2.  Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.

Authors:  Hideko Goto; Hisashi Tsurumi; Masao Takemura; Yoriko Ino-Shimomura; Senji Kasahara; Michio Sawada; Toshiki Yamada; Takeshi Hara; Kenji Fukuno; Naoe Goto; Masataka Okuno; Tsuyoshi Takami; Mitsuru Seishima; Hisataka Moriwaki
Journal:  J Cancer Res Clin Oncol       Date:  2004-10-21       Impact factor: 4.553

3.  Prognostic significance of biochemical markers in African Burkitt's lymphoma.

Authors:  F K N Arthur; L Owusu; F A Yeboah; T Rettig; A Osei-Akoto
Journal:  Clin Transl Oncol       Date:  2011-10       Impact factor: 3.405

4.  Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP.

Authors:  Takeshi Hara; Hisashi Tsurumi; Naoe Goto; Nobuhiro Kanemura; Takeshi Yoshikawa; Senji Kasahara; Toshiki Yamada; Michio Sawada; Hideko Goto; Kenji Fukuno; Jun-Ichi Kitagawa; Ichiro Yasuda; Naoki Katsumura; Masao Takemura; Takeshi Takahashi; Tsuyoshi Takami; Hisataka Moriwaki
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-21       Impact factor: 4.553

5.  Impact of serum levels of IL-18 and soluble IL-2 receptor on the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP regimen.

Authors:  Hussein M Khaled; Thoraya M Abdelhamid; Fouad M Abu-Taleb; Niveen M El-Hifnawi; Ahmad B Waley
Journal:  Future Sci OA       Date:  2019-08-28

6.  Patient-Proxy Agreement Regarding Health-Related Quality of Life in Survivors with Lymphoma: A Propensity-Score Matching Analysis.

Authors:  Richard Huan Xu; Dong Dong
Journal:  Cancers (Basel)       Date:  2022-01-25       Impact factor: 6.639

7.  Changes in Incidence and Survival by Decade of Patients With Primary Colorectal Lymphoma: A SEER Analysis.

Authors:  Qingguo Li; Shaobo Mo; Weixing Dai; Yaqi Li; Ye Xu; Xinxiang Li; Guoxiang Cai; Sanjun Cai
Journal:  Front Public Health       Date:  2020-10-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.